We conclude that GSTM1 could be a potential biomarker for predicting or possible optimising the response to SPRMs treatment for the clinical management of uterine leiomyoma, which could save economic burden and impove quality of life for affectedwomen. This evidence concerns the gene GSTM1 and Uterine leiomyoma.